Dr. Subhash Thuluva
 | The topic of this article may not meet Wikitia's general notability guideline. |
Subhash Thuluva | |
|---|---|
| Add a Photo | |
| Nationality | Indian |
| Education | PhD in Clinical Pharmacology |
| Alma mater | University in Germany (unspecified) |
| Occupation | Clinical researcher, pharmaceutical executive |
| Employer | Biological E. Limited |
| Known for | Vaccine development, public health research |
Subhash Thuluva is an Indian pharmaceutical executive and clinical researcher. He is currently the Senior Vice President and Head of Clinical Development at Biological E. Limited, a Hyderabad-based biopharmaceutical company. Thuluva has over two decades of experience in clinical research and drug development and has contributed to several vaccine development programs in India, including during the COVID-19 pandemic.
Education and early career
Thuluva completed his undergraduate education in pharmacy in India before pursuing higher studies in Germany. He earned a master's degree and a PhD in clinical pharmacology, with a focus on pharmacogenetics—the study of how individual genetic differences affect drug response.
Career
After completing his education, Thuluva returned to India and held various roles in leading pharmaceutical companies:
- At Ranbaxy, he worked in medical affairs and conducted clinical trials for Indian submissions.
- At Allergan, he led the development center in Bangalore, focusing on neuro-urological studies.
- At Novartis, he was responsible for large-scale international clinical trials in rheumatology.
- At Clinigene (now Syngene), he oversaw clinical operations.
- At Quintiles, he held a senior leadership position in clinical development.
He joined Biological E. Limited to lead its clinical development and pharmacovigilance efforts.
Contributions to vaccine development
During the COVID-19 pandemic, Thuluva was part of the core leadership team responsible for designing and managing the clinical trials for Biological E’s COVID-19 vaccine candidates. He described the experience as intense and challenging, particularly due to the need to conduct on-site trials during lockdowns.[1]
Research and publications
Thuluva was a lead author on a peer-reviewed clinical study published in 2024 evaluating the safety and immunogenicity of PNEUBEVAX 14™, a 14-valent pneumococcal conjugate vaccine developed by Biological E. The study focused on healthy Indian infants and demonstrated favorable safety and immune response profiles.<ref>{{cite journal |last1=Thuluva |first1=Subhash |title=Immunogenicity and Safety of Biological E’s 14-valent Pneumococcal Conjugate Vaccine (PNEUBEVAX 14™) in Healthy Indian Infants |journal=Human Vaccines & Immunotherapeutics |date=April 2024 |doi=10.1080/21645515.2024.2335844 |pmid=38637211
References
- ↑ "The Untold Story of India's COVID-19 Vaccine Trials". Pharma Now. Retrieved 2025-05-15.
External links
This article "Dr. Subhash Thuluva" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.